Argenx
ARGX
#473
Rank
NZ$92.64 B
Marketcap
NZ$1,473
Share price
0.78%
Change (1 day)
5.52%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): NZ$27.23

According to Argenx 's latest financial reports the company's current EPS (TTM) is NZ$28.23. In 2025 the company made an earnings per share (EPS) of NZ$37.64 an increase over its 2024 EPS that were of NZ$24.86.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$27.23-27.67%
2025NZ$37.6451.44%
2024NZ$24.86-369.77%
2023NZ-$9.21-60.46%
2022NZ-$23.3063.33%
2021NZ-$14.27-40.37%
2020NZ-$23.93183.47%
2019NZ-$8.44123.09%
2018NZ-$3.7854.93%
2017NZ-$2.4414.07%
2016NZ-$2.1413.05%
2015NZ-$1.89-36.34%
2014NZ-$2.97209.04%
2013NZ-$0.96-33.99%
2012NZ-$1.46185.59%
2011NZ-$0.51